These results indicate that FBP1 is suppressed in some patients with ccRCC and that FBP1 might play a critical role during tumor development of ccRCC and possibly can serve as a novel molecular biomarker for ccRCC. This evidence concerns the gene FBP1 and nonpapillary renal cell carcinoma.